The pharmaceutical company iuvo Therapeutics, founded in 2017 and headquartered in Düsseldorf, pursues the goal of reliably supplying patients in Europe with cannabis-based medicine of the highest quality. To achieve this goal, iuvo, as an independent importer, manufacturer, and wholesaler, constantly expands its manufacturer partnerships and supply chains, which have been successfully GDP and GMP certified for years.

Pharmacies and a selection of pharmaceutical wholesalers are part of iuvo‘s distribution network. The company develops its pharmaceuticals based on the state of science and in cooperation with experts in cannabis therapy, supports doctors and pharmaceutical specialists through recognized, scientific training courses. iuvo Therapeutics is an active member of the Federal Association of Pharmaceutical Cannabinoid Companies.

Central EU Supply Hub

Imported, qualified & distributed from the heart of Europe

By successfully adhering to the highest quality standards and releasing the product for sale in Germany, iuvo has strategically positioned itself to be able to service the growing EU market.

Companies that have chosen to release products in another EU country have been facing frequent recalls, product adoption issues and regulatory barriers.

Through a partnership with the logistics specialist Med-X-Press GmbH, iuvo ensures access to its pharma- ceuticals in Germany with a 24h distribution network extending to over 20,000 pharmacies.

Beyond German borders iuvo cooperates with domestic groups in France, Poland, UK, Ireland, Italy, Lithuania, and many more as regulatory frameworks change.

Harmonized Regulatory Frameworks Across the EU

The strategic licence and logistic partnerships of iuvo enable distribution across the EU without regulatory challenges.

Highest Level of Pharmaceutical Compliance

Products are imported, qualified and market released for sale in Germany under review of our Qualified Person (QP) & the renowned pharmaceutical agency of North Rhine-Westphalia.

First Mover Advantage as Countries Open

As cannabinoid therapies become an option for more patients across the EU, iuvo will be able to deliver a tested product portfolio to domestic wholesalers, pharmacies and research entities alike.

Diverse Revenue Streams

Focus on high-margin downstream operations

iuvo is a manufacturer independent EU access-hub for cannabinoid medicines. The Company services both the EU pharmaceutical wholesale (B2B) and direct-to-pharmacy (B2C) markets. A diversified product portfolio and an array of ancillary services such as EU-GMP consulting or white label options enable iuvo to take advantage of several revenue streams simultaneously.

Direct-to-Pharmacy

iuvo can service over 20,000 pharmacies in Germany with 24h shipments. The Company has successfully established supply relationships with the 15 leading dispensing pharmacies in the country.

EU Pharma-Wholesale

iuvo has secured supply agreements with several leading pharmaceutical wholesalers. The Company achieved this by offering high quality products at competitive pricing and white- label options for a preferred list of partners.

EU-GMP Service Partner

Our pharmaceutical IP and strategic licenses enable us to be selective with our supply partnerships and uphold a competitive advantage in the EU. iuvo secure favorable contract conditions including royalty fees or EU-GMP consulting contracts and more.

The iuvo Management Team

Left to right: Jonathan Lubosch-H., Daniel Seidl, Alexander Rieg, Jakob Herrenberger